Articles tagged with Myocarditis
Researchers found 23 men in the U.S. military developed severe chest pain and elevated cardiac troponin levels within four days of receiving a second dose of mRNA COVID-19 vaccines, but most recovered quickly. The risk of myocarditis from vaccination is low compared to COVID-19 infection.
Researchers report on seven patients hospitalized for acute myocarditis-like illness following COVID-19 vaccination. All symptoms resolved before hospital discharge after treatment with beta-blocker and anti-inflammatory medications.
A study of 1,597 Big Ten athletes revealed a notable increase in the detection of myocarditis following COVID-19 infection, highlighting the importance of cardiac screening. Cardiac magnetic resonance imaging proved to be an effective tool for identifying this condition, a leading cause of sudden death in competitive athletes.
Researchers at CNIC have discovered a specific blood marker for myocarditis, allowing clinicians to distinguish the disease from other cardiomyopathies. The biomarker, miR-721, was validated in numerous hospitals and has high sensitivity and specificity (>90%) for myocarditis diagnosis.
A study by Vanderbilt University Medical Center found lower degrees of myocarditis in athletes with a history of COVID-19 compared to previously reported rates. The research highlights the importance of considering cardiac MRI as an additional screening tool for detecting myocarditis in athletes.
A comprehensive review of research studies on SARS-CoV-2 infections in infants less than 3 months old found that the majority experience mild to moderate cases and usually recover with supportive care. No deaths were reported, contradicting earlier findings suggesting myocarditis as a rare but possible complication.
Researchers found that the rate of myocarditis caused by COVID-19 is between 1.4% and 7.2%, significantly lower than previously reported rates. This finding should inform clinical colleagues about interpreting blood tests and heart radiology studies.
Fulminant myocarditis, a rare condition causing severe inflammation of the heart, is increasingly being recognized due to advancements in technology. Early recognition, circulatory support, and maintenance of end-organ function can lead to favorable outcomes for patients with fulminant myocarditis.
Researchers have identified midkine as a key driver of inflammation in the heart muscle that can lead to heart failure in patients with myocarditis. The study found that inhibiting midkine reduced neutrophil infiltration and improved heart function.
Cardiovascular complications, including myocarditis and pericarditis, have been identified in patients treated with immune checkpoint inhibitors. The study also found a link between vasculitis and visual impairment, highlighting the need for clinicians to monitor for these conditions.
Researchers at Osaka University found that the immune system promotes spontaneous heart regeneration after myocarditis. Cardiomyocytes can proliferate under specific conditions, such as inflammation, and this process is mediated by factors like STAT3 and interleukin 11.
Researchers found that eosinophils play a key role in the progression of heart muscle inflammation to heart failure in mice. The study suggests that eosinophils may be responsible for the deterioration of heart muscle function, even in the absence of severe inflammation.
Researchers found that myocarditis is affecting both children and adults worldwide, with men being twice as likely as women to develop severe reactions. Early diagnosis is key to preventing long-term heart damage, and new investigational therapies are soon to be tested.
Viral myocarditis is a leading cause of sudden unexpected death from cardiovascular causes, particularly in men under 40 years old. Chronic myocarditis can lead to dilated cardiomyopathy requiring heart transplantation, with up to 30% of cases resulting from underlying viral infections.
Researchers found elevated levels of translocator protein 18 kDa (TSPO) in patients with myocarditis and mice, suggesting its potential as a biomarker for heart inflammation. TSPO's role in driving disease progression and prognosis is also being explored.
A new blood thinner, Dabigatran etexilate (Pradaxa), may increase the risk and severity of certain viral infections, including flu and myocarditis. Researchers found that blocking thrombin activity can disturb the innate immune response to viral infection.
The new guidelines aim to provide a framework for early recognition and treatment of pediatric heart failure, which often goes unrecognized until it's too late. The guidelines recommend specialized care, including echocardiography by a pediatric specialist, and evidence-based treatments such as diuretics and inotropic drugs.
Researchers discovered that autoimmune disease myocarditis occurs when immune system targets heart muscle cells expressing alpha myosin, a protein required for contraction. Preventing the disease involves exposing T cells to alpha myosin in thymus, suggesting measurement of alpha-myosin as diagnostic tool and potential therapeutic target
A 44-year-old sailor received a groundbreaking treatment for severe myocarditis, which caused inflammation of his heart muscle and led to heart failure. He was implanted with two small ventricular assist devices, making him the first person in North America to receive this life-saving therapy.
Several new diagnostic methods, such as cardiac magnetic resonance imaging (MRI), are useful for diagnosing myocarditis. Endomyocardial biopsy is also used in certain cases. The study highlights the importance of these methods in improving diagnosis accuracy.
Researchers at MDC Berlin-Buch discovered a mechanism to prevent viral myocarditis by blocking the Coxsackie-adenovirus-receptor. Genetically engineered mice without this receptor were protected from cardiac infection caused by the Coxsackievirus, showing that autoimmune response may not be the primary cause of disease process.
A recent study has found a link between smallpox vaccination and rare heart diseases, including pericarditis and myocarditis. Twenty-four cases of these conditions were identified among 37,876 US civilian healthcare workers who received the vaccine as part of a bioterrorism readiness program.
Myocarditis is an inflammatory condition that can trigger an autoimmune response, leading to heart failure. Researchers have identified complement and its receptors as key players in this process, shedding light on potential therapeutic approaches for treatment of human autoimmune diseases.
Researchers at UCLA have discovered a new treatment that can reverse heart damage in children with acute myocarditis, an infection of the heart. The study used OKT3, an immunosuppressive treatment, to suppress the immune response and improve heart function in five critically ill children.
A study led by Johns Hopkins researchers found that patients with fulminant myocarditis can fully recover from the condition within two weeks without much damage to the heart or chance of relapse. Effective treatments include medications and mechanical pumps, which can increase blood flow and assist heart function.
A study by Johns Hopkins Medicine found that cases of life-threatening heart muscle inflammation are declining in the US, corresponding with a decline in enteroviral infections. Since 1991, myocarditis was present in less than 5% of patients biopsied each year, correlating with reduced enterovirus cases reported by the CDC.
Researchers at Johns Hopkins Medicine found adenovirus in 71.4% of autopsied hearts from patients with viral myocarditis, a condition previously attributed to Coxsackie B enterovirus. The study suggests adenovirus and enteroviruses may work together to cause this condition.